NCT06615128Not yet recruiting
Assessment of Serum CD25 Level in Systemic Sclerosis Patients with or Without Interstitial Lung Disease (ILD)
Source: ClinicalTrials.gov · Last updated 26 Sept 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Assessment of serum level of sCD25 in SSc (with or without ILD) and its correlation with disease activity. Evaluating the clinical correlation of serum soluble CD25 (sCD25) in systemic sclerosis (SSc) (with or without ILD).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 66 (estimated)
- First submitted
- 24 Sept 2024
- Start date
- 1 Oct 2024
- Primary completion date
- 1 Oct 2026
- Lead sponsor
- Assiut University
- Diseases
- Systemic sclerosis (scleroderma)
- NCT number
- NCT06615128
What you commit to
- Study type: Observational
- Planned participants: 66
- From 1 Oct 2024 to the primary completion date, 1 Oct 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Inclusion criteria:
- SSc patients fulfilled the 2013 ACR/EU LAR criteria (10). Adult age above 18 years.
- Exclusion criteria:
- Patients unwilling to participate in the study.
- Patients with other autoimmune diseases.
- Patients with interstitial lung disease (ILD) caused by causes other than systemic sclerosis.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.